MEDIA OUTREACH NEWSWIRE Novartis Piqray® – First and Only Rreatment Specially for Patients with a PIK3CA Mutation in HR+/HER2- Advanced Breast Cancer Receives HSA Approval 1 Maret 20213 Maret 2021
